Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study.
clinical pharmacology
epidemiology
primary care
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
23 03 2021
23 03 2021
Historique:
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
20
5
2021
Statut:
epublish
Résumé
The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort. MultiCare was conducted as a longitudinal cohort study in primary care, located in eight different study centres in Germany. 3189 patients (59.3% female). Baseline data were used for the following analyses. Drugs were classified according to the well-established anticholinergic drug scale (ADS) and the recently published German anticholinergic burden (German ACB). Cognitive function was measured using a letter digit substitution test (LDST) and a mixed-effect multivariate linear regression was performed to calculate the influence of anticholinergic burden on the cognitive function. Patients used 1764 anticholinergic drugs according to ADS and 2750 anticholinergics according to the German ACB score (prevalence 38.4% and 53.7%, respectively). The mean ADS score was 0.8 (±1.3), and the mean German ACB score was 1.2 (±1.6) per patient. The most common ADS anticholinergic was furosemide (5.8%) and the most common ACB anticholinergic was metformin (13.7%). The majority of the identified anticholinergics were drugs with low anticholinergic potential: 80.2% (ADS) and 73.4% (ACB), respectively. An increasing ADS and German ACB score was associated with reduced cognitive function according to the LDST (-0.26; p=0.008 and -0.24; p=0.003, respectively). Multimorbid elderly patients are in a high risk for using anticholinergic drugs according to ADS and German ACB score. We especially need to gain greater awareness for the contribution of drugs with low anticholinergic potential from the cardiovascular system. As anticholinergic drug use is associated with reduced cognitive function in multimorbid elderly patients, the importance of rational prescribing and also deprescribing needs to be further evaluated. ISRCTN89818205.
Identifiants
pubmed: 33757948
pii: bmjopen-2020-044230
doi: 10.1136/bmjopen-2020-044230
pmc: PMC7993236
doi:
Substances chimiques
Cholinergic Antagonists
0
Pharmaceutical Preparations
0
Banques de données
ISRCTN
['ISRCTN89818205']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e044230Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Med. 2009 Dec;122(12):1142-1149.e1-2
pubmed: 19958893
Expert Opin Drug Saf. 2016 Jun;15(6):753-68
pubmed: 26966981
Eur J Clin Pharmacol. 2015 Nov;71(11):1299-314
pubmed: 26350641
J Clin Psychiatry. 2019 Aug 6;80(4):
pubmed: 31390497
Eur J Clin Pharmacol. 2015 Nov;71(11):1389-96
pubmed: 26300207
Drugs Aging. 2016 Nov;33(11):809-818
pubmed: 27638818
Br J Clin Pharmacol. 2013 Mar;75(3):842-9
pubmed: 22924454
Eur J Clin Pharmacol. 2020 Mar;76(3):319-335
pubmed: 31832732
Drugs Aging. 2018 Jun;35(6):523-538
pubmed: 29736815
Annu Rev Clin Psychol. 2009;5:363-89
pubmed: 19327033
Int J Clin Pharm. 2019 Feb;41(1):167-178
pubmed: 30659492
Implement Sci. 2017 Aug 1;12(1):99
pubmed: 28764753
Alzheimers Res Ther. 2017 Aug 1;9(1):58
pubmed: 28764796
BMC Geriatr. 2015 Mar 25;15:31
pubmed: 25879993
BMC Geriatr. 2018 Oct 11;18(1):239
pubmed: 30305048
Drugs Aging. 2018 Jan;35(1):61-71
pubmed: 29335932
BMJ Open. 2018 Jul 6;8(7):e022500
pubmed: 29982221
J Clin Pharmacol. 2006 Dec;46(12):1481-6
pubmed: 17101747
JAMA Intern Med. 2015 Mar;175(3):401-7
pubmed: 25621434
J Am Geriatr Soc. 2015 Jan;63(1):85-90
pubmed: 25597560
J Nutr Health Aging. 2017;21(4):389-396
pubmed: 28346565
Drugs Aging. 2015 Feb;32(2):159-67
pubmed: 25566958
Curr Pharm Des. 2018;24(28):3384-3391
pubmed: 29589542
Drugs Aging. 2019 Oct;36(10):957-967
pubmed: 31359329
Aging Clin Exp Res. 2016 Feb;28(1):25-35
pubmed: 25930085
PLoS One. 2014 Jan 13;9(1):e83224
pubmed: 24454696
Drugs Aging. 2018 Jan;35(1):83-91
pubmed: 29322470
J Am Geriatr Soc. 2008 Dec;56(12):2203-10
pubmed: 19093918
Psychol Rev. 1996 Jul;103(3):403-28
pubmed: 8759042
PLoS One. 2019 Feb 12;14(2):e0212046
pubmed: 30753214
Pharmacotherapy. 2016 Nov;36(11):1123-1131
pubmed: 27711982
Perm J. 2020;24:
pubmed: 31905333
BMC Health Serv Res. 2012 Apr 03;12:89
pubmed: 22471952
PLoS One. 2017 Feb 10;12(2):e0171353
pubmed: 28187171
J Neurol. 2019 Jul;266(7):1816-1818
pubmed: 31197512
Drugs Aging. 2019 Mar;36(3):289-297
pubmed: 30652263
BMC Fam Pract. 2018 Jul 28;19(1):131
pubmed: 30055583
Int J Geriatr Psychiatry. 2017 Jun;32(6):650-656
pubmed: 27280553
BMC Health Serv Res. 2009 Aug 11;9:145
pubmed: 19671164
PLoS One. 2016 Mar 21;11(3):e0151084
pubmed: 26999286
Drugs Aging. 2018 Mar;35(3):223-232
pubmed: 29404965
PLoS One. 2018 Oct 31;13(10):e0205897
pubmed: 30379948
BMJ. 2018 Apr 25;361:k1315
pubmed: 29695481
BMJ. 2006 Feb 25;332(7539):455-9
pubmed: 16452102